Thrombolytics, anticoagulants, and antiplatelet agents.
Ringleb
Peter A
PA
University of Heidelberg, Germany. peter_ringleb@med.uni-heidelberg.de
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000925:Anticoagulants / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D013923:Thromboembolism / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000379:methods*
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; C426686:ximelagatran; D000077284:Abciximab